A surprising no to both multiple myeloma uses puts the ball in the FDA's court.
ApexOnco Front Page
Recent articles
The group has canned its first-generation project, hoping that a follow-on will reach more patients.
So far ASP3082 looks no better than Jiangsu HengRui’s straight KRAS G12D inhibitor.
The small cap biotech Instil Bio tries to follow in Summit’s slipstream.
Early data suggest that PD-(L)1 x VEGF bispecifics might challenge Keytruda in triple-negative disease.
Patients' expression of CEACAM5 might hold the key to activity after all.
Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.
Spectrum’s poziotinib failed in HER2 exon 20 lung cancer, but that isn’t stopping Boehringer and Bayer.